181 related articles for article (PubMed ID: 21175440)
1. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.
Helsby NA; Hui CY; Goldthorpe MA; Coller JK; Soh MC; Gow PJ; De Zoysa JZ; Tingle MD
Br J Clin Pharmacol; 2010 Dec; 70(6):844-53. PubMed ID: 21175440
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.
Winoto J; Song H; Hines C; Nagaraja H; Rovin BH
Clin Nephrol; 2011 May; 75(5):451-7. PubMed ID: 21543025
[TBL] [Abstract][Full Text] [Related]
3. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.
Xie HJ; Yasar U; Lundgren S; Griskevicius L; Terelius Y; Hassan M; Rane A
Pharmacogenomics J; 2003; 3(1):53-61. PubMed ID: 12629583
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Helsby N; Yong M; Burns K; Findlay M; Porter D
Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism.
Crane AL; Klein K; Zanger UM; Olson JR
Toxicology; 2012 Mar; 293(1-3):115-122. PubMed ID: 22281205
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.
Xie H; Griskevicius L; Ståhle L; Hassan Z; Yasar U; Rane A; Broberg U; Kimby E; Hassan M
Eur J Pharm Sci; 2006 Jan; 27(1):54-61. PubMed ID: 16183265
[TBL] [Abstract][Full Text] [Related]
7. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
8. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
[TBL] [Abstract][Full Text] [Related]
10. Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation.
Melanson SE; Stevenson K; Kim H; Antin JH; Court MH; Ho VT; Ritz J; Soiffer RJ; Kuo FC; Longtine JA; Jarolim P
Am J Hematol; 2010 Dec; 85(12):967-71. PubMed ID: 21108329
[No Abstract] [Full Text] [Related]
11. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
12. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
13. Which CYP2B6 variants have functional consequences for cyclophosphamide bioactivation?
Helsby NA; Tingle MD
Drug Metab Dispos; 2012 Mar; 40(3):635-7. PubMed ID: 22159699
[No Abstract] [Full Text] [Related]
14. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Xu C; Ogburn ET; Guo Y; Desta Z
Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
[TBL] [Abstract][Full Text] [Related]
15. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Helsby NA; Yong M; van Kan M; de Zoysa JR; Burns KE
Br J Clin Pharmacol; 2019 Sep; 85(9):1925-1934. PubMed ID: 31218720
[TBL] [Abstract][Full Text] [Related]
16. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
[TBL] [Abstract][Full Text] [Related]
17. Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers.
Ellison CA; Abou El-Ella SS; Tawfik M; Lein PJ; Olson JR
J Toxicol Environ Health A; 2012; 75(4):232-41. PubMed ID: 22352331
[TBL] [Abstract][Full Text] [Related]
18. Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
Raccor BS; Claessens AJ; Dinh JC; Park JR; Hawkins DS; Thomas SS; Makar KW; McCune JS; Totah RA
Drug Metab Dispos; 2012 Jan; 40(1):54-63. PubMed ID: 21976622
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]